Treatment Naïve, Chronic HCV

Peginterferon alfa-2b + Ribavirin for 12 or 24 Weeks in GT 2,3

Peginterferon alfa-2b + RBV for 12 or 24 Weeks in GT 2 or 3 Study Design

**Study**
- Randomized, open-label trial
- Conducted in 12 centers in Italy

**Subjects**
- N = 283 with chronic hepatitis C
- Treatment naïve adult patients
- Genotype 2 or 3

**Regimens**
- Peginterferon alfa-2b: 1.0 μg/kg/wk + Ribavirin: 1000-1200 mg/d x 24 wks
- Peginterferon alfa-2b: 1.0 μg/kg/wk + Ribavirin: 1000-1200 mg/d x 12 or 24 wks*

**Primary Endpoint**
- Undetectable serum HCV RNA at end of treatment (ETR)
- Undetectable serum HCV RNA 24 wks after cessation of treatment (SVR)

*Duration based on whether week 4 HCV RNA negative (12 weeks) or positive (24 weeks)

Peginterferon alfa-2b + RBV for 12 or 24 Weeks in GT 2 or 3
Treatment Duration and Ribavirin Dose

Week 0  12  24  36  48

Standard: All received 24 week of treatment
N = 70
Peginterferon alfa-2b + Ribavirin

Variable: Duration based on Week 4 HCV RNA (negative = 12 week Rx; positive = 24 week Rx)
N = 76
Peginterferon alfa-2b + Ribavirin

N = 132
Peginterferon alfa-2b + Ribavirin

Drug Dosing
Peginterferon alfa-2b: 1.5 μg/kg 1x/week
Ribavirin (divided bid): <75 kg (1000 mg/day); ≥75 kg (1200 mg/day)

Peginterferon alfa-2b + RBV for 12 or 24 Weeks in GT 2 or 3
Treatment Duration and Ribavirin Dose

SVR24 Rates, by Regimen

<table>
<thead>
<tr>
<th></th>
<th>Standard 24-Weeks</th>
<th>Variable 12-Weeks</th>
<th>Variable 24-Weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>76</td>
<td>85</td>
<td>64</td>
</tr>
<tr>
<td>Genotype 2</td>
<td>76</td>
<td>87</td>
<td>72</td>
</tr>
<tr>
<td>Genotype 3</td>
<td>76</td>
<td>77</td>
<td>41</td>
</tr>
</tbody>
</table>

Patients with SVR (%)

Conclusions: “A shorter course of therapy over 12 weeks with peginterferon alfa-2b and ribavirin is as effective as a 24-week course for patients with HCV genotype 2 or 3 who have a response to treatment at 4 weeks.”
This slide deck is from the University of Washington’s *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online

[www.hepatitisc.uw.edu](http://www.hepatitisc.uw.edu)

Hepatitis Web Study


Funded by a grant from the Centers for Disease Control and Prevention.